Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2010 - 2026)

Celldex Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 52.93% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $51.9 million (up 52.93% YoY), while the FY2025 annual figure was $51.8 million, up 23.68% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $51.9 million, roughly flat from $51.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $51.9 million in Q1 2026, with the low at $15.4 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $32.1 million (2023), against an average of $31.4 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 104.19% in 2022, then sank 46.61% in 2023.
• Celldex Therapeutics' Total Non-Current Liabilities stood at $21.2 million in 2022, then surged by 51.21% to $32.1 million in 2023, then jumped by 30.6% to $41.9 million in 2024, then grew by 23.68% to $51.8 million in 2025, then increased by 0.27% to $51.9 million in 2026.
• Business Quant data shows CLDX's Total Non-Current Liabilities at $51.9 million in Q1 2026, $51.8 million in Q4 2025, and $47.5 million in Q3 2025.